» Articles » PMID: 27146887

Prescription Opioid Injection Among HIV-Positive People Who Inject Drugs in a Canadian Setting

Overview
Journal AIDS Behav
Date 2016 May 6
PMID 27146887
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Prescription opioids (POs) are commonly prescribed to patients living with HIV/AIDS, while the illicit use of POs remains a major public health concern throughout Canada and the United States. We sought to identify the prevalence and correlates of PO injection among HIV-positive people who inject drugs (PWID) in Vancouver, Canada, where HIV/AIDS treatment and care is offered at no cost. We examined data from 634 individuals from an ongoing prospective cohort of HIV-positive PWID. Between December 2005 and November 2013, the median prevalence of recent PO injection was 24.2 % [interquartile range (IQR): 21.5-25.8 %]. In a multivariable generalized estimating equation model, Caucasian ethnicity, heroin injection, and drug dealing were positively associated with PO injection, while older age and methadone maintenance treatment were negatively associated with PO injection (all p < 0.05). Engagement on antiretroviral therapy was inversely associated with PO injection in a bivariable analysis, but did not remain significant after adjusting for heroin injection. These findings describe a particularly vulnerable sub-group of PWID who may benefit from targeted efforts to both minimize drug-related risk behaviors and support HIV/AIDS treatment.

Citing Articles

Social determinants of ethno-racial inequalities in substance use: a decomposition of national survey data.

Blair A, Siddiqi A Soc Psychiatry Psychiatr Epidemiol. 2022; 57(10):2013-2022.

PMID: 35482051 DOI: 10.1007/s00127-022-02281-3.


Morphine and HIV-1 Tat interact to cause region-specific hyperphosphorylation of tau in transgenic mice.

Ohene-Nyako M, Nass S, Hahn Y, Knapp P, Hauser K Neurosci Lett. 2020; 741:135502.

PMID: 33202259 PMC: 7750279. DOI: 10.1016/j.neulet.2020.135502.

References
1.
Inciardi J, Surratt H, Cicero T, Kurtz S, Martin S, Parrino M . The "black box" of prescription drug diversion. J Addict Dis. 2010; 28(4):332-47. PMC: 2824903. DOI: 10.1080/10550880903182986. View

2.
Degenhardt L, Black E, Breen C, Bruno R, Kinner S, Roxburgh A . Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. Drug Alcohol Rev. 2006; 25(5):403-12. DOI: 10.1080/09595230600868504. View

3.
Rosenblum A, Parrino M, Schnoll S, Fong C, Maxwell C, Cleland C . Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007; 90(1):64-71. DOI: 10.1016/j.drugalcdep.2007.02.012. View

4.
Hammig R, Kohler W, Bonorden-Kleij K, Weber B, Lebentrau K, Berthel T . Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. J Subst Abuse Treat. 2014; 47(4):275-81. DOI: 10.1016/j.jsat.2014.05.012. View

5.
Darke S, Williamson A, Ross J, Teesson M . Non-fatal heroin overdose, treatment exposure and client characteristics: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev. 2005; 24(5):425-32. DOI: 10.1080/09595230500286005. View